mRNA THERAPY PRODUCTS

MANUFACTURING, QUALITY AND REGULATORY CONSIDERATIONS

2025

KNOWLEDGE SHARING AND **CAPACITY BUILDING**

- ***Increased communication and education*** with public/patient advocacy groups xRNA-based therapeutics.
- ***Standardization and control*** of starting and raw materials.
- ***Increased collaboration*** – within the industry and also between regulators and industry (balance specificity with flexibility).
- Expand process & product knowledge to ***create a robust control strategy***.
- ***Utilization of prior knowledge and platform technologies*** when justified.

SYMPOSIUM ON MRNA 2025 **BY THE NUMBERS**

Total Attendees

71

Regulatory Participation

3

Company Representation

46

Country Collaboration

6

Austria | Canada | Netherlands | Switzerland | United Kingdom | United States

CASSS RESOURCES

Looking for more past meeting content?

Speaker slides, roundtable notes, and video presentations can be accessed through **Papers and Presentations** and **CASSS On Demand** on our website. **www.casss.org**

CASSS™
SHARING SCIENCE **SOLUTIONS**